Loading
NASDAQHealthcareBiotechnology
Latest quote
$21.08
+$0.52 · +2.53%
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Latest quote
$21.08
+$0.52 · +2.53%
After-hours
$21.00
−$0.08 · -0.38%
Oct 9, 4:59 PM ET
Regular session · ET · Market data may be delayed.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Day range
Current $21.08
52-week range
Current $21.08
Regular session · ET · Market data may be delayed.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Day range
Current $21.08
52-week range
Current $21.08
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 181K USD | 830K USD | 490K USD | 441K USD |
| Gross profit | — | −181K USD | −830K USD | −490K USD | −441K USD |
| Research and development | 201.19M USD | 6.4M USD | 23.77M USD | 48.21M USD | 38.49M USD |
| Selling, general, and administrative | 9.69M USD | 10.32M USD | 11.86M USD | 12.51M USD | 13.3M USD |
| Operating expenses | 210.87M USD | 16.72M USD | 35.63M USD | 60.72M USD | 51.79M USD |
| Interest income | 1.17M USD | 844K USD | 1.69M USD | 722K USD | 156K USD |
| Depreciation and amortization | 34K USD | 181K USD | 830K USD | 490K USD | 441K USD |
| Operating income | −210.87M USD | −16.9M USD | −36.46M USD | −61.21M USD | −52.23M USD |
| Net income | −209.84M USD | −21.44M USD | −38.35M USD | −61.62M USD | −51.75M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM25.65M0.03%77.7B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI15.44M0.15%10.11B USD0.35%$153.77+3.00%
Vanguard Russell 2000 ETFVTWO8.65M0.05%18B USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO6.21M0.05%14.04B USD0.24%$356.78+0.94%
Vanguard Extended Market ETFVXF6.06M0.01%95.4B USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA5.32M0.02%21.73B USD0.03%$32.79+0.40%
iShares Russell 2000 Value ETFIWN2.79M0.02%13.75B USD0.24%$210.87-0.04%
iShares Core S&P Total U.S. Stock Market ETFITOT1.46M0.00%97.8B USD0.03%$169.66+0.64%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Value ETFIWNiShares Core S&P Total U.S. Stock Market ETFITOTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
